SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Lupin receives USFDA's approval for generic Clobex Spray

27 Mar 2018 Evaluate

Lupin has received final approval for its Clobetasol Propionate Spray, 0.05% from the United States Food and Drug Administration (USFDA) to market a generic version of Galderma Laboratories, L.P.'s Clobex Spray, 0.05%.

Clobetasol Propionate Spray, 0.05% had annual sales of around $30.5 million in the US (IQVIA MAT January 2018).

Lupin's Clobetasol Propionate Spray, 0.05% is the generic equivalent of Galderma Laboratories, L.P.'s Clobex Spray, 0.05%. It is indicated for the treatment of moderate to severe plaque psoriasis affecting up to 20% body surface area (BSA) in patients 18 years of age or older.

Lupin is an innovation led transnational pharmaceutical company developing and delivering a wide range of branded & generic formulations, biotechnology products and APIs globally.

Lupin Share Price

2377.90 -81.85 (-3.33%)
08-May-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1847.30
Dr. Reddys Lab 1293.25
Cipla 1347.70
Zydus Lifesciences 938.90
Lupin 2377.90
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×